Jeffrey Freeman is an Endocrinology/Metabolic physician affiliated with Philadelphia College of Osteopathic Medicine. OpenAlex indexes 44 publications with 531 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4190 City Ave
Suite 324
Philadelphia, PA 191311626
Telephone
215-871-1916Registry record last updated 21 Feb 2013.
Industry payments
66 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year202520 payments
- Mannkind CorporationProgram year202516 payments
- Amgen Inc.Program year202517 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
53.4%Insulin Analog17.8%Lantus Solostar24%Novolog Flexpen16%Tresiba Flextouch U-10013%Basaglar Kwikpen U-1007%Humalog Kwikpen U-1007%Levemir Flexpen6%Tresiba Flextouch U-2004%Insulin Lispro Kwikpen U-1004%Novolog4%Lantus4%Humalog3%Toujeo Solostar3%Insulin Aspart Flexpen2%Toujeo Max Solostar2%Lyumjev Kwikpen U-1001%Fiasp Flextouch1%Part D<11 patientsGLP-1 receptor agonist9.8%Ozempic52%Trulicity27%Mounjaro13%Rybelsus8%Part D≥58 patients+ 11 more classes in this area
Cardiovascular
21.8%Statin10.1%Atorvastatin Calcium52%Rosuvastatin Calcium25%Simvastatin23%Part D≥85 patientsCholesterol absorption inhibitor3.1%Ezetimibe100%Part D≥52 patients+ 11 more classes in this area
Hormonal (systemic)
21.4%l-Thyroxine16.1%Levothyroxine Sodium79%Synthroid21%Part D≥188 patientsThyroid Hormone Synthesis Inhibitor4.7%Methimazole95%Propylthiouracil5%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Noah May, DO
Philadelphia College of Osteopathic Medicine
Joseph Kaczmarczyk, DO
Philadelphia College of Osteopathic Medicine
Katherine Galluzzi, DO
Philadelphia College of Osteopathic Medicine
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”